Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Cybin Inc.
< Previous
1
2
3
4
5
6
7
Next >
Cybin Announces EMBARK Open Access, the First Free Online Course Providing Facilitator Training for Psychedelic Therapy
April 12, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate in the Oppenheimer 33rd Annual Healthcare Conference
March 08, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin and The Chopra Foundation to Participate in Featured Session at Upcoming 2023 South by Southwest® Conference
March 02, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Positive Data from its CYB003 Phase 1/2a Trial and Provides Update on its CYB004 Development Program
February 28, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Streamlined Clinical Alignment
February 22, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Inc. Reports Third Quarter Financial Results and Recent Business Highlights
February 14, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Approval of First-in-Human Dosing of its Proprietary DMT Molecule CYB004
February 01, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Host Virtual R&D Day on February 28, 2023
January 26, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Promising Results from Sponsored Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain
January 18, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Selects Generalized Anxiety Disorder as Target Indication for Deuterated DMT Molecule CYB004
January 12, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Outlines Upcoming Priorities and Milestones for its Clinical Development Programs
January 08, 2023
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Highlights 2022 Accomplishments and Milestones
December 20, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Presents CYB003 Preclinical Data at 2022 American College of Neuropsychopharmacology Annual Meeting
December 06, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Inc. Presents CYB003 Preclinical Data at Neuroscience 2022
November 15, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Inc. Reports Second Quarter Financial Results and Recent Business Highlights
November 14, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Provides Progress Update on its CYB004-E Phase 1 Trial
November 10, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate in the Jefferies London Healthcare Conference and Upcoming Investor Events
November 03, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Scientific Presentation at the 5th Annual Neuropsychiatric & Psychedelics Drug Development Summit
November 01, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin’s EMBARK Program Announces Graduation of Facilitators
October 27, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin & The Chopra Foundation Recognize World Mental Health Day
October 10, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Provides Update on its Intellectual Property Portfolio
October 06, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Obtains Exclusive License to a Novel Catalog of Psychedelic-Based Compounds
September 27, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate in Upcoming Scientific and Investor Conferences
September 21, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Achieves Research and Development Milestones Ahead of Projected Timelines
September 20, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Final Adelia Milestone Achievement
August 31, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Inc. Announces First Participants Dosed in its Phase 1/2a Trial of CYB003 for the Treatment of Major Depressive Disorder
August 30, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
August 25, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin and Clinilabs Granted Schedule I DEA License for CYB003 Phase 1/2a First-In-Human Clinical Trial
August 17, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
Cybin Announces Results of Shareholders’ Meeting
August 15, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
CORRECTING and REPLACING Cybin Announces Up to USD$35 Million At-The-Market Equity Program
August 08, 2022
From
Cybin Inc.
Via
Business Wire
Tickers
CYBN
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.